Skip to main content

Table 2 The clinical information of 178 CMML patients classified as CMML-0, -1, and -2

From: Mutational landscape of chronic myelomonocytic leukemia in Chinese patients

Variables

CMML-0

(n = 65)

CMML-1

(n = 58)

CMML-2

(n = 55)

P value

0 vs. 1

0 vs. 2

1 vs. 2

Age in years; median (range)

65 (24–86)

62 (23–82)

59 (17–90)

0.085

–

–

–

Sex (male); n (%)

41 (63.1%)

43 (73.1%)

34 (61.8%)

0.383

–

–

–

Hemoglobin (g/L); median (range)

89 (53–173)

82 (38–153)

84.0 (39–131)

0.049

0.267

0.058

1.000

WBC (×109/L); median (range)

9.32 (1.38–158.9)

12.79 (3.15–177.7)

23.7 (1.22-323.66)

0.007

1.000

0.007

0.068

ANC (×109/L); median (range)

4.66 (0.51–32)

3.92 (0.45–20.62)

6.35 (1.06–29.97)

0.606

–

–

–

AMC (×109/L); median (range)

2.4 (1.11–6.5)

2.43 (1.01–6.45)

2.85 (1.01–16.32)

0.600

–

–

–

Platelets(×109/L); median (range)

101 (11–977)

66 (6-900)

62 (3-610)

0.015

0.046

0.037

1.000

LDH (IU/ml); median (range)

230.5 (120–1403)

266 (152.4–623)

352 (121.6–1298)

0.046

1.000

0.097

0.136

Cytogenetic risk groupa; n (%)

 Low-risk

55 (84.6%)

38 (65.5%)

36 (65.5%)

0.023

0.014

0.015

0.994

 Intermediate-risk

5 (7.7%)

7 (12.1%)

6 (10.9%)

0.704

–

–

–

 High-risk

5 (7.7%)

13 (22.4%)

13 (23.6%)

0.034

0.021

0.015

0.877

Splenomegaly; n (%)

16 (28.6%)

12 (26.1%)

14 (30.4%)

0.898

–

–

–

Treatment strategy; n (%)

 Best supportive care

17 (51.5%)

6 (23.1%)

5 (15.2%)

0.004

0.034

0.004

0.512

 HMAs ± chemotherapy/allo-HSCT

16 (48.5%)

20 (76.9%)

28 (84.8%)

    
  1. (WHO CMML-0: PB < 2%, BM < 5%; CMML-1: PB = 2–4%, BM = 5–9%; CMML-2: PB = 5–9%, BM = 10–19%)
  2. aCytogenetic risk groups [1, 2]: low-risk: a diploid karyotype or -Y; high-risk: trisomy 8, alterations of chromosome 7, as well as complex karyotype; intermediate-risk: all other karyotypes